One    O
domain    O
facilitates    O
the    O
ATP    O
-    O
grasp    O
mechanism    O
and    O
the    O
other    O
is    O
the    O
catalytic    O
active    O
site    O
for    O
γ-glutamylcysteine    B-DerivedFunction106014730
.    O

Remacemide    B-DerivedFunction106014730
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
low    O
-    O
affinity    O
NMDA    O
antagonist    O
with    O
sodium    O
channel    O
blocking    O
properties    O
.    O

Compounds    O
that    O
have    O
failed    O
to    O
prevent    O
or    O
slow    O
progression    O
of    O
Huntington    O
's    O
disease    O
in    O
human    O
trials    O
include    O
remacemide    B-DerivedFunction106014730
,    O
coenzyme    O
Q10    O
,    O
riluzole    O
,    O
creatine    O
,    O
minocycline    O
,    O
ethyl    O
-    O
EPA    O
,    O
phenylbutyrate    O
and    O
dimebon    O
.    O

Some    O
anticonvulsants    O
including    O
:    O
carbamazepine    O
,    O
ethosuximide    O
,    O
phenytoin    O
,    O
topiramate    B-DerivedFunction106014730
,    O
valproate    O
.    O

:*    O
topiramate    B-DerivedFunction106014730

Topiramate    B-DerivedFunction106014730
,    O
GABA    O
-    O
receptor    O
related    O
anticonvulsant    O
and    O
mood    O
-    O
stabilizer    O

Some    O
new    O
antiepileptic    O
drugs    O
such    O
as    O
topiramate    B-DerivedFunction106014730
,    O
gabapentin    O
,    O
and    O
lamotrigine    O
have    O
already    O
been    O
developed    O
and    O
have    O
shown    O
promise    O
in    O
treatment    O
of    O
PTE    O
.    O

Cimetidine    O
,    O
omeprazole    O
,    O
oxcarbazepine    O
,    O
ticlopidine    O
,    O
topiramate    B-DerivedFunction106014730
,    O
ketoconazole    O
,    O
itraconazole    O
,    O
disulfiram    O
,    O
fluvoxamine    O
,    O
isoniazid    O
,    O
erythromycin    O
,    O
probenecid    O
,    O
propranolol    O
,    O
imipramine    O
,    O
ciprofloxacin    O
,    O
fluoxetine    O
,    O
and    O
valproic    O
acid    O
prolong    O
the    O
action    O
of    O
diazepam    O
by    O
inhibiting    O
its    O
elimination    O
.    O

Examples    O
of    O
drugs    O
commonly    O
associated    O
with    O
depressogenic    O
effects    O
include    O
some    O
anticonvulsants    O
such    O
as    O
the    O
barbiturates    O
(    O
e.g.    O
phenobarbital    O
)    O
,    O
benzodiazepines    O
(    O
e.g.    O
diazepam    O
)    O
,    O
vigabatrin    O
,    O
and    O
topiramate    B-DerivedFunction106014730
,    O
corticosteroids    O
like    O
dexamethasone    O
and    O
prednisone    O
,    O
cytokines    O
like    O
interferon-α    O
and    O
interleukin-2    O
,    O
certain    O
antihypertensives    O
such    O
as    O
amiodarone    O
,    O
clonidine    O
,    O
methyldopa    O
,    O
reserpine    O
,    O
and    O
tetrabenazine    O
(    O
used    O
as    O
an    O
antipsychotic    O
/    O
antihyperkinetic    O
)    O
,    O
and    O
agents    O
with    O
antiandrogen    O
,    O
antiestrogen    O
,    O
and/or    O
anti    O
-    O
neurosteroid    O
activities    O
such    O
as    O
GnRH    O
agonists    O
(    O
e.g.    O
,    O
leuprolide    O
,    O
goserelin    O
)    O
,    O
anastrozole    O
(    O
an    O
aromatase    O
inhibitor    O
)    O
,    O
finasteride    O
(    O
a    O
5α-reductase    O
inhibitor    O
)    O
,    O
and    O
clomiphene    O
(    O
a    O
SERM    O
)    O
,    O
as    O
well    O
as    O
others    O
including    O
flunarizine    O
,    O
mefloquine    O
,    O
and    O
efavirenz    O
.    O

Topiramate    B-DerivedFunction106014730
,    O
an    O
anti    O
-    O
epileptic    O
drug    O
,    O
has    O
been    O
used    O
to    O
treat    O
excoriation    O
disorder    O
;    O
in    O
a    O
small    O
study    O
of    O
individuals    O
with    O
Prader–    O

Zonisamide    O
has    O
been    O
studied    O
for    O
and    O
used    O
as    O
a    O
migraine    O
preventative    O
medication    O
,    O
when    O
topiramate    B-DerivedFunction106014730
is    O
either    O
ineffective    O
or    O
can    O
not    O
be    O
continued    O
due    O
to    O
side    O
effects    O
.    O

Zonisamide    O
and    O
other    O
carbonic    O
anhydrase    O
inhibitors    O
such    O
as    O
topiramate    B-DerivedFunction106014730
,    O
furosemide    O
,    O
and    O
hydrochlorothiazide    O
have    O
been    O
known    O
to    O
interfere    O
with    O
amobarbital    O
,    O
which    O
has    O
led    O
to    O
inadequate    O
anesthetization    O
during    O
the    O
Wada    O
test    O
.    O

Though    O
antiepileptic    O
drugs    O
(    O
membrane    O
-    O
stabilizing    O
drugs    O
)    O
such    O
as    O
pregabalin    O
,    O
gabapentin    O
,    O
topiramate    B-DerivedFunction106014730
,    O
and    O
lamotrigine    O
improve    O
symptoms    O
,    O
there    O
is    O
no    O
effective    O
permanent    O
or    O
long    O
-    O
term    O
treatment    O
for    O
SUNCT    O
.    O

An    O
anticonvulsant    O
called    O
topiramate    B-DerivedFunction106014730
has    O
helped    O
patients    O
in    O
three    O
cases    O
and    O
may    O
be    O
a    O
viable    O
treatment    O
for    O
the    O
future    O
.    O

Controlled    O
clinical    O
trials    O
of    O
gabapentin    O
yielded    O
mixed    O
results    O
in    O
efficacy    O
against    O
essential    O
tremor    O
while    O
topiramate    B-DerivedFunction106014730
was    O
shown    O
to    O
be    O
effective    O
in    O
a    O
larger    O
double    O
-    O
blind    O
controlled    O
study    O
,    O
resulting    O
in    O
both    O
lower    O
Fahn    O
-    O
Tolosa    O
-    O
Marin    O
tremor    O
scale    O
ratings    O
and    O
better    O
function    O
and    O
disability    O
as    O
compared    O
to    O
placebo    O
.    O

The    O
T    O
-    O
DNA    O
carries    O
genes    O
for    O
the    O
biosynthetic    O
enzymes    O
for    O
the    O
production    O
of    O
unusual    O
amino    O
acids    O
,    O
typically    O
octopine    B-DerivedFunction106014730
or    O
nopaline    B-DerivedFunction106014730
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
methylamine    O
and    O
L    O
-    O
glutamate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
NH3    O
and    O
N-methyl-L-glutamate    B-DerivedFunction106014730
.    O

In    O
the    O
first    O
step    O
of    O
galactose    O
metabolism    O
,    O
galactose    O
is    O
converted    O
to    O
galactose-1-phosphate    B-DerivedFunction106014730
(    O
Gal-1-P    O
)    O
by    O
the    O
enzyme    O
galactokinase    O
.    O

Galactokinase    O
then    O
phosphorylates    O
α-D    O
-    O
galactose    O
at    O
the    O
1    O
'    O
hydroxyl    O
group    O
,    O
yielding    O
galactose-1-phosphate    B-DerivedFunction106014730
.    O

Proinsulin    O
undergoes    O
maturation    O
into    O
active    O
insulin    O
through    O
the    O
action    O
of    O
cellular    O
endopeptidases    O
known    O
as    O
prohormone    O
convertases    O
(    O
PC1    O
and    O
PC2    O
)    O
,    O
as    O
well    O
as    O
the    O
exoprotease    O
carboxypeptidase    O
E.    O
The    O
endopeptidases    O
cleave    O
at    O
2    O
positions    O
,    O
releasing    O
a    O
fragment    O
called    O
the    O
C-peptide    B-DerivedFunction106014730
,    O
and    O
leaving    O
2    O
peptide    O
chains    O
,    O
the    O
B-    O
and    O
A-    O
chains    O
,    O
linked    O
by    O
2    O
disulfide    O
bonds    O
.    O

The    O
C-peptide    B-DerivedFunction106014730
is    O
the    O
central    O
portion    O
of    O
proinsulin    O
,    O
and    O
the    O
primary    O
sequence    O
of    O
proinsulin    O
goes    O
in    O
the    O
order    O
"    O
B    O
-    O
C    O
-    O
A    O
"    O
(    O
the    O
B    O
and    O
A    O
chains    O
were    O
identified    O
on    O
the    O
basis    O
of    O
mass    O
and    O
the    O
C    O
-    O
peptide    O
was    O
discovered    O
later    O
)    O
.    O

Of    O
these    O
markers    O
,    O
nPOD    O
tests    O
for    O
C-Peptide    B-DerivedFunction106014730
,    O
autoantibodies    O
,    O
and    O
HLA    O
.    O

Finally    O
,    O
proinsulin    O
is    O
converted    O
into    O
the    O
bioactive    O
hormone    O
insulin    O
by    O
removal    O
of    O
the    O
C-peptide    B-DerivedFunction106014730
.    O

Levothyroxine    B-DerivedFunction106014730
,    O
also    O
known    O
as    O
-thyroxine    B-DerivedFunction106014730
,    O
is    O
a    O
manufactured    O
form    O
of    O
the    O
thyroid    O
hormone    O
,    O
thyroxine    O
(    O
T4    O
)    O
.    O

The    O
generic    O
name    O
is    O
levothyroxine    B-DerivedFunction106014730
,    O
and    O
several    O
brands    O
are    O
available    O
.    O

Levothyroxine    B-DerivedFunction106014730
,    O
by    O
the    O
trade    O
name    O
"    O
Letter    O
"    O

Physicians    O
are    O
cautioned    O
to    O
avoid    O
switching    O
patients    O
from    O
branded    O
to    O
generic    O
,    O
or    O
between    O
different    O
generic    O
manufacturers    O
,    O
when    O
prescriping    O
anti    O
-    O
epileptic    O
drugs    O
,    O
warfarin    O
,    O
and    O
levothyroxine    B-DerivedFunction106014730
.    O

After    O
the    O
removal    O
of    O
a    O
thyroid    O
,    O
patients    O
usually    O
take    O
a    O
prescribed    O
oral    O
synthetic    O
thyroid    O
hormone    O
—    O
levothyroxine    B-DerivedFunction106014730
(    O
Synthroid)—to    O
prevent    O
hypothyroidism    O
.    O

Women    O
with    O
symptoms    O
or    O
a    O
very    O
high    O
TSH    O
level    O
,    O
or    O
both    O
,    O
are    O
usually    O
prescribed    O
a    O
course    O
of    O
levothyroxine    B-DerivedFunction106014730
.    O

Animals    O
resistant    O
to    O
weight    O
loss    O
,    O
despite    O
diet    O
and    O
exercise    O
changes    O
,    O
can    O
be    O
placed    O
on    O
levothyroxine    B-DerivedFunction106014730
to    O
increase    O
metabolism    O
.    O

Levothyroxine    B-DerivedFunction106014730

:    O
acetyl    O
-    O
CoA    O
+    O
carnitine    O
CoA    O
+    O
acetylcarnitine    B-DerivedFunction106014730

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
and    O
carnitine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
O    O
-    O
acetylcarnitine    B-DerivedFunction106014730
.    O

VidaLinux    B-DerivedFunction106014730

Streptozotocin    B-DerivedFunction106014730

Streptozotocin    B-DerivedFunction106014730
is    O
used    O
in    O
islet    O
cell    O
carcinomas    O
which    O
produce    O
excessive    O
insulin    O
.    O

Doxorubicin    O
and    O
streptozotocin    B-DerivedFunction106014730
have    O
also    O
been    O
used    O
successfully    O
to    O
selectively    O
damage    O
alpha    O
cells    O
of    O
the    O
pancreatic    O
islets    O
.    O

However    O
,    O
T2D    O
in    O
model    O
organisms    O
are    O
introduced    O
via    O
surgery    O
of    O
partial/    O
whole    O
pancreas    O
,    O
or    O
using    O
chemicals    O
such    O
as    O
Streptozotocin    B-DerivedFunction106014730
.    O

Streptozocin    B-DerivedFunction106014730

The    O
primary    O
metabolites    O
are    O
amphetamine    O
and    O
4-hydroxymethamphetamine    O
;    O
other    O
minor    O
metabolites    O
include    O
:    O
,    O
,    O
,    O
benzoic    O
acid    O
,    O
hippuric    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
,    O
norephedrine    O
,    O
and    O
phenylacetone    O
,    O
the    O
metabolites    O
of    O
amphetamine    O
.    O

S.    O
pyogenes    O
"    O
is    O
CAMP    O
and    O
hippurate    B-DerivedFunction106014730
tests    O
negative    O
.    O

An    O
early    O
synthesis    O
by    O
Buck    O
and    O
co    O
-    O
workers    O
began    O
with    O
3,4-dimethoxybenzaldehyde    O
(    O
veratraldehyde    O
)    O
,    O
which    O
was    O
condensed    O
with    O
hippuric    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
to    O
give    O
the    O
azlactone    O
;    O
this    O
was    O
hydrolyzed    O
with    O
NaOH    O
to    O
the    O
corresponding    O
pyruvic    O
acid    O
,    O
which    O
was    O
then    O
converted    O
to    O
its    O
oxime    O
;    O
treatment    O
of    O
the    O
oxime    O
with    O
acetic    O
anhydride    O
gave    O
3,4-dimethoxyphenylacetonitrile    O
,    O
which    O
was    O
catalytically    O
reduced    O
(    O
H2/Pd    O
)    O
in    O
the    O
presence    O
of    O
excess    O
dimethylamine    O
to    O
N    O
,    O
N    O
-    O
dimethyl-3,4-dimethoxyphenethylamine    O
;    O
finally    O
,    O
the    O
methoxy    O
-    O
groups    O
were    O
cleaved    O
with    O
HCl    O
to    O
give    O
DMDA    O
as    O
its    O
hydrochloride    O
salt    O
.    O

This    O
enzyme    O
plays    O
a    O
prominent    O
role    O
in    O
converting    O
benzoic    O
acid    O
(    O
benzoate    O
)    O
into    O
hippuric    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
(    O
N    O
-    O
benzoylglycine    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
benzoyl    O
-    O
CoA    O
and    O
glycine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N-benzoylglycine    B-DerivedFunction106014730
.    O

It    O
is    O
formed    O
by    O
6-phosphogluconolactonase    O
,    O
and    O
acted    O
upon    O
by    O
phosphogluconate    O
dehydrogenase    O
to    O
produce    O
ribulose    B-DerivedFunction106014730
5-phosphate    I-DerivedFunction106014730
.    O

The    O
last    O
step    O
of    O
the    O
oxidative    O
reactions    O
in    O
the    O
pentose    O
phosphate    O
pathway    O
is    O
the    O
production    O
of    O
ribulose    B-DerivedFunction106014730
5-phosphate    I-DerivedFunction106014730
.    O

It    O
is    O
a    O
ketose    O
sugar    O
formed    O
from    O
ribulose-5-phosphate    B-DerivedFunction106014730
.    O

In    O
patients    O
with    O
deficiency    O
of    O
transaldolase    O
,    O
there    O
's    O
an    O
accumulation    O
of    O
erythritol    O
(    O
from    O
erythrose    B-DerivedFunction106014730
4-phosphate    I-DerivedFunction106014730
)    O
,    O
D    O
-    O
arabitol    O
,    O
and    O
ribitol    O
.    O

This    O
cleavage    O
reaction    O
generates    O
the    O
unusual    O
aldose    O
sugar    O
erythrose-4-phosphate    B-DerivedFunction106014730
.    O

Erythrose    B-DerivedFunction106014730
4-phosphate    I-DerivedFunction106014730
is    O
a    O
phosphate    O
of    O
the    O
simple    O
sugar    O
erythrose    O
.    O

In    O
the    O
Calvin    O
cycle    O
aldolase    O
also    O
catalyzes    O
the    O
production    O
of    O
sedoheptulose    O
1,7-bisphosphate    O
from    O
DHAP    O
and    O
erythrose    B-DerivedFunction106014730
4-phosphate    I-DerivedFunction106014730
.    O

The    O
chromosomal    O
background    O
of    O
EHA101    O
is    O
C58C1    O
,    O
a    O
cured    O
nopaline    B-DerivedFunction106014730
strain    O
.    O

The    O
sequon    O
is    O
an    O
Asn    O
-    O
X    O
-    O
Ser    O
or    O
Asn    O
-    O
X    O
-    O
Thr    O
sequence    O
,    O
where    O
X    O
is    O
any    O
amino    O
acid    O
except    O
proline    O
and    O
the    O
glycan    O
may    O
be    O
composed    O
of    O
"    O
N    O
"-    O
acetylgalactosamine    O
,    O
galactose    O
,    O
neuraminic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
,    O
"    O
N    O
"-    O
acetylglucosamine    O
,    O
fucose    O
,    O
mannose    O
,    O
and    O
other    O
monosaccharides    O
.    O

Modification    O
reactions    O
may    O
involve    O
the    O
addition    O
of    O
a    O
phosphate    O
or    O
acetyl    O
group    O
onto    O
the    O
sugars    O
,    O
or    O
the    O
addition    O
of    O
new    O
sugars    O
,    O
such    O
as    O
neuraminic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
.    O

Viral    O
neuraminidase    O
cleaves    O
terminal    O
neuraminic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
(    O
also    O
called    O
sialic    O
acid    O
)    O
residues    O
from    O
glycan    O
structures    O
on    O
the    O
surface    O
of    O
the    O
infected    O
cell    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D-ribose    B-DerivedFunction106014730
5-phosphate    I-DerivedFunction106014730
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
D    O
-    O
ribose    O
1,5-bisphosphate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D    O
-    O
ribose    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
D-ribose    B-DerivedFunction106014730
5-phosphate    I-DerivedFunction106014730
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ADP    O
and    O
D-ribose    B-DerivedFunction106014730
5-phosphate    I-DerivedFunction106014730
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
ADP    O
-    O
ribose    O
.    O

Ribose    B-DerivedFunction106014730
5-phosphate    I-DerivedFunction106014730
is    O
both    O
a    O
product    O
and    O
an    O
intermediate    O
of    O
the    O
pentose    O
phosphate    O
pathway    O
.    O

mitobronitol    B-DerivedFunction106014730
(    O
INN    O
)    O

Studies    O
have    O
shown    O
this    O
treatment    O
combined    O
with    O
valacyclovir    B-DerivedFunction106014730
to    O
be    O
effective    O
in    O
combating    O
HSV-1    O
and    O
eventually    O
returning    O
lymphocyte    O
counts    O
to    O
normal    O
.    O

Since    O
herpes    O
infections    O
often    O
lead    O
to    O
pleocytosis    O
,    O
aciclovir    O
and    O
valacyclovir    B-DerivedFunction106014730
are    O
commonly    O
prescribed    O
.    O

Valaciclovir    B-DerivedFunction106014730
,    O
also    O
spelled    O
valacyclovir    B-DerivedFunction106014730
,    O
is    O
an    O
antiviral    O
drug    O
used    O
in    O
the    O
management    O
of    O
herpes    O
simplex    O
,    O
herpes    O
zoster    O
(    O
shingles    O
)    O
,    O
and    O
herpes    O
B.    O

Purine    O
analogues    O
of    O
guanine    O
:    O
Aciclovir    O
,    O
Famciclovir    O
,    O
Ganciclovir    O
,    O
Penciclovir    O
,    O
Valaciclovir    B-DerivedFunction106014730
,    O
Valganciclovir    B-DerivedFunction106014730

9-Carboxymethoxymethylguanine    O
(    O
CMMG    O
)    O
is    O
a    O
compound    O
which    O
is    O
known    O
as    O
the    O
principal    O
metabolite    O
of    O
the    O
antiviral    O
drug    O
acyclovir    O
(    O
and    O
its    O
prodrug    O
valacyclovir    B-DerivedFunction106014730
)    O
,    O
and    O
has    O
been    O
suggested    O
as    O
the    O
causative    O
agent    O
in    O
the    O
neuropsychiatric    O
side    O
effects    O
sometimes    O
associated    O
with    O
these    O
drugs    O
.    O

In    O
the    O
case    O
of    O
herpetic    O
uveitis    O
,    O
anti    O
-    O
viral    O
medications    O
,    O
such    O
as    O
valaciclovir    B-DerivedFunction106014730
or    O
aciclovir    O
,    O
may    O
be    O
administered    O
to    O
treat    O
the    O
causative    O
viral    O
infection    O
.    O

It    O
is    O
also    O
known    O
as    O
cascara    B-DerivedFunction106014730
,    O
from    O
the    O
Spanish    O
"    O
cáscara    O
"    O
,    O
meaning    O
"    O
husk    O
"    O
.    O

It    O
is    O
a    O
structural    O
analogue    O
of    O
2-C-methyl-D-erythrose    B-DerivedFunction106014730
4-phosphate    I-DerivedFunction106014730
.    O

They    O
made    O
several    O
discoveries    O
critical    O
to    O
understanding    O
carbohydrate    O
metabolism    O
,    O
including    O
the    O
isolation    O
and    O
discovery    O
of    O
the    O
Cori    B-DerivedFunction106014730
ester    I-DerivedFunction106014730
,    O
glucose-1    O
phosphate    O
,    O
and    O
the    O
understanding    O
of    O
the    O
Cori    O
cycle    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
beta-D-glucose    B-DerivedFunction106014730
1-phosphate    I-DerivedFunction106014730
,    O
and    O
one    O
product    O
,    O
beta    O
-    O
D    O
-    O
glucose    O
6-phosphate    O
.    O

Galactose    O
is    O
therefore    O
preferentially    O
converted    O
into    O
glucose-1-phosphate    B-DerivedFunction106014730
,    O
which    O
may    O
be    O
shunted    O
into    O
glycolysis    O
or    O
the    O
inositol    O
synthesis    O
pathway    O
.    O

The    O
enzyme    O
removes    O
1,4    O
glycosyl    O
residues    O
from    O
outer    O
branches    O
of    O
glycogen    O
and    O
adds    O
inorganic    O
phosphate    O
to    O
form    O
glucose-1-phosphate    B-DerivedFunction106014730
.    O

They    O
include    O
allosteric    O
enzymes    O
that    O
catalyze    O
the    O
production    O
of    O
glucose-1-phosphate    B-DerivedFunction106014730
from    O
a    O
glucan    O
such    O
as    O
glycogen    O
,    O
starch    O
or    O
maltodextrin    O
.    O

G6PD    O
converts    O
glucose-6-phosphate    B-DerivedFunction106014730
into    O
6-phosphoglucono-δ-lactone    O
and    O
is    O
the    O
rate    O
-    O
limiting    O
enzyme    O
of    O
this    O
metabolic    O
pathway    O
that    O
supplies    O
reducing    O
energy    O
to    O
cells    O
by    O
maintaining    O
the    O
level    O
of    O
the    O
reduced    O
form    O
of    O
the    O
co    O
-    O
enzyme    O
nicotinamide    O
adenine    O
dinucleotide    O
phosphate    O
(    O
NADPH    O
)    O
.    O

More    O
precisely    O
,    O
it    O
facilitates    O
the    O
interconversion    O
of    O
glucose    B-DerivedFunction106014730
1-phosphate    I-DerivedFunction106014730
and    O
glucose    B-DerivedFunction106014730
6-phosphate    I-DerivedFunction106014730
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
D-glucose    B-DerivedFunction106014730
6-phosphate    I-DerivedFunction106014730
,    O
and    O
one    O
product    O
,    O
1D    O
-    O
myo    O
-    O
inositol    O
3-phosphate    O
.    O

The    O
glucose-1-phosphate    O
generated    O
in    O
step    O
3    O
of    O
the    O
Leloir    O
pathway    O
may    O
be    O
isomerized    O
to    O
glucose-6-phosphate    B-DerivedFunction106014730
by    O
phosphoglucomutase    O
.    O

G6PD    B-DerivedFunction106014730
reduces    O
NADP+    O
to    O
NADPH    O
while    O
oxidizing    O
glucose-6-phosphate    O
.    O

Reaction    O
1    O
is    O
a    O
pretreatment    O
of    O
the    O
sample    O
performed    O
by    O
adding    O
glucokinase    O
to    O
convert    O
glucose    O
to    O
glucose    B-DerivedFunction106014730
6-phosphate    I-DerivedFunction106014730
in    O
the    O
presence    O
of    O
adenosine    O
triphosphate    O
,    O
pyruvate    O
kinase    O
,    O
and    O
phosphoenol    O
pyruvate    O
.    O

G6Pase    O
is    O
located    O
in    O
the    O
endoplasmic    O
reticulum    O
(    O
ER    O
)    O
and    O
catalyzes    O
the    O
hydrolysis    O
of    O
glucose    B-DerivedFunction106014730
6-phosphate    I-DerivedFunction106014730
to    O
glucose    O
and    O
phosphate    O
in    O
the    O
last    O
step    O
of    O
the    O
gluconeogenic    O
and    O
glycogenolytic    O
pathways    O
.    O

The    O
glucose    O
that    O
enters    O
the    O
β-cell    O
is    O
phosphorylated    O
to    O
glucose-6-phosphate    B-DerivedFunction106014730
(    O
G-6-P    O
)    O
by    O
glucokinase    O
(    O
hexokinase    O
IV    O
)    O
which    O
is    O
not    O
inhibited    O
by    O
G-6-P    O
in    O
the    O
way    O
that    O
the    O
hexokinases    O
in    O
other    O
tissues    O
(    O
hexokinase    O
I    O
–    O

The    O
heterotrophic    O
processing    O
of    O
carbohydrates    O
involves    O
isomerization    O
of    O
triose    O
phosphates    O
and    O
interconversion    O
between    O
fructose-6-phosphate    O
and    O
glucose-6-phosphate    B-DerivedFunction106014730
.    O

It    O
is    O
produced    O
from    O
glucose-6-phosphate    B-DerivedFunction106014730
by    O
glucose-6-phosphate    O
dehydrogenase    O
.    O

Incognito    B-DerivedFunction106014730
–    O
includes    O
anonymity    O
and    O
security    O
tools    O
such    O
as    O
Tor    O
by    O
default    O

Desoxyfructo-serotonin    B-DerivedFunction106014730
is    O
a    O
leprostatic    O
agent    O
.    O

Purine    O
analogues    O
of    O
guanine    O
:    O
Aciclovir    O
,    O
Famciclovir    O
,    O
Ganciclovir    O
,    O
Penciclovir    O
,    O
Valaciclovir    B-DerivedFunction106014730
,    O
Valganciclovir    B-DerivedFunction106014730

In    O
terms    O
of    O
the    O
treatment    O
of    O
cytomegalovirus    O
retinitis    O
,    O
oral    O
valganciclovir    B-DerivedFunction106014730
,    O
intravenous    O
ganciclovir    O
,    O
IV    O
foscarnet    O
,    O
and    O
IV    O
cidofovir    O
are    O
all    O
efficient    O
in    O
the    O
treatment    O
of    O
this    O
condition    O
.    O

Calculate    B-DerivedFunction106014730
Linux    I-DerivedFunction106014730

A    O
topical    O
cream    O
combining    O
alprostadil    O
with    O
the    O
permeation    O
enhancer    O
DDAIP    B-DerivedFunction106014730
has    O
been    O
approved    O
in    O
Canada    O
under    O
the    O
brand    O
name    O
Vitaros    O
as    O
a    O
first    O
line    O
treatment    O
for    O
erectile    O
dysfunction    O
.    O

Other    O
examples    O
of    O
monobactams    O
are    O
tigemonam    O
,    O
nocardicin    B-DerivedFunction106014730
A    I-DerivedFunction106014730
,    O
and    O
tabtoxin    B-DerivedFunction106014730
.    O

SystemRescueCD    B-DerivedFunction106014730

For    O
Windows    O
users    O
,    O
Partimage    O
includes    O
experimental    O
support    O
for    O
NTFS    O
.    O
Partimage    O
supports    O
most    O
common    O
Linux    O
file    O
systems    O
,    O
and    O
can    O
be    O
found    O
in    O
many    O
Linux    O
distributions    O
,    O
including    O
Debian    O
and    O
the    O
live    O
distros    O
PING    O
,    O
Knoppix    O
and    O
SystemRescueCD    B-DerivedFunction106014730
.    O

Chloralose    B-DerivedFunction106014730
(    O
a    O
narcotic    O
prodrug    O
)    O

:    O
D11AX09    O
Oxaceprol    B-DerivedFunction106014730

Some    O
cells    O
in    O
culture    O
grow    O
better    O
on    O
surfaces    O
coated    O
with    O
positive    O
charge    O
like    O
poly-L-lysine    B-DerivedFunction106014730
or    O
polyornithine    O
or    O
Alcian    O
blue    O
.    O

From    O
studies    O
that    O
have    O
applied    O
this    O
method    O
to    O
poly    B-DerivedFunction106014730
(L-lysine)    I-DerivedFunction106014730
,    O
ELS    O
is    O
believed    O
to    O
monitor    O
fluctuation    O
mobilities    O
in    O
the    O
presence    O
of    O
solvents    O
with    O
varying    O
salt    O
concentrations    O
.    O

milacemide    B-DerivedFunction106014730
(    O
INN    O
)    O

PAH    O
(    O
"para"-aminohippurate    B-DerivedFunction106014730
)    O
is    O
freely    O
filtered    O
,    O
is    O
not    O
reabsorbed    O
,    O
and    O
is    O
secreted    O
within    O
the    O
nephron    O
.    O

When    O
using    O
a    O
compound    O
with    O
an    O
extraction    O
ratio    O
near    O
1    O
,    O
such    O
as    O
para-aminohippurate    B-DerivedFunction106014730
(    O
PAH    O
)    O
,    O
eRPF    O
approximates    O
RPF    O
.    O

Ututo    B-DerivedFunction106014730

The    O
residue    O
of    O
lysine-142    O
in    O
the    O
active    O
site    O
of    O
transaldolase    O
forms    O
a    O
Schiff    O
base    O
with    O
the    O
keto    O
group    O
in    O
sedoheptulose-7-phosphate    B-DerivedFunction106014730
after    O
deprotonation    O
by    O
another    O
active    O
site    O
residue    O
,    O
glutamate-106    O
.    O

Sedoheptulose    B-DerivedFunction106014730
7-phosphate    I-DerivedFunction106014730
is    O
an    O
intermediate    O
in    O
the    O
pentose    O
phosphate    O
pathway    O
.    O

("S")-3,4-DCPG    B-DerivedFunction106014730
:    O
agonist    O

Triiodothyronine    O
is    O
formed    O
,    O
when    O
diiodotyrosine    O
is    O
combined    O
with    O
monoiodotyrosine    B-DerivedFunction106014730
(    O
in    O
the    O
colloid    O
of    O
the    O
thyroid    O
follicle    O
)    O
.    O

Monoiodotyrosine    B-DerivedFunction106014730
is    O
a    O
precursor    O
of    O
thyroid    O
hormone    O
and    O
results    O
from    O
halogenation    O
of    O
tyrosine    O
at    O
the    O
meta    O
-    O
position    O
of    O
the    O
benzene    O
ring    O
.    O

"N"-Formylmethionine    B-DerivedFunction106014730

IF2    O
binds    O
to    O
an    O
initiator    B-DerivedFunction106014730
tRNA    I-DerivedFunction106014730
and    O
controls    O
the    O
entry    O
of    O
tRNA    O
onto    O
the    O
ribosome    O
.    O

It    O
binds    O
to    O
the    O
small    O
16S    O
rRNA    O
of    O
the    O
30S    O
subunit    O
of    O
the    O
bacterial    O
ribosome    O
,    O
interfering    O
with    O
the    O
binding    O
of    O
formyl-methionyl-tRNA    B-DerivedFunction106014730
to    O
the    O
30S    O
subunit    O
.    O

These    O
receptors    O
were    O
originally    O
identified    O
by    O
their    O
ability    O
to    O
bind    O
N    O
-    O
formyl    O
peptides    O
such    O
as    O
"N"-formylmethionine    B-DerivedFunction106014730
produced    O
by    O
the    O
degradation    O
of    O
either    O
bacterial    O
or    O
host    O
cells    O
.    O

Studies    O
conducted    O
in    O
the    O
1970s    O
found    O
that    O
a    O
series    O
of    O
N-Formylmethionine    B-DerivedFunction106014730
-    O
containing    O
oligopeptides    O
,    O
including    O
the    O
most    O
potent    O
and    O
best    O
known    O
member    O
of    O
this    O
series    O
,    O
N    O
-    O
formyl    O
-    O
methionyl    O
-    O
leucyl    O
-    O
phenylalanine    O
(    O
FMLP    O
or    O
fMet    O
-    O
Leu    O
-    O
Phe    O
)    O
,    O
stimulated    O
rabbit    O
and    O
human    O
neutrophils    O
by    O
an    O
apparent    O
receptor    O
-    O
dependent    O
mechanism    O
to    O
migrate    O
in    O
a    O
directional    O
pattern    O
in    O
classical    O
laboratory    O
assays    O
of    O
chemotaxis    O
.    O

Examples    O
of    O
EAARIs    O
include    O
dihydrokainic    O
acid    O
(    O
DHK    O
)    O
and    O
WAY-213,613    B-DerivedFunction106014730
,    O
selective    O
blockers    O
of    O
EAAT2    O
(    O
GLT-1    O
)    O
,    O
and    O
L-"trans"-2,4-PDC    O
,    O
a    O
non    O
-    O
selective    O
blocker    O
of    O
all    O
five    O
EAATs    O
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
isonocardicin    O
A    O
,    O
and    O
one    O
product    O
,    O
nocardicin    B-DerivedFunction106014730
A    I-DerivedFunction106014730

Aceglutamide    B-DerivedFunction106014730

Other    O
medications    O
have    O
been    O
shown    O
to    O
be    O
useful    O
in    O
topical    O
treatment    O
of    O
refractory    O
ulcers    O
,    O
including    O
glycosaminoglycans    O
such    O
as    O
sodium    O
hyaluronate    O
and    O
chondroitin    O
sulfate    O
,    O
aminocaproic    O
acid    O
,    O
and    O
acetylcysteine    B-DerivedFunction106014730
.    O

Treatment    O
includes    O
antibiotics    O
and    O
collagenase    O
inhibitors    O
such    O
as    O
acetylcysteine    B-DerivedFunction106014730
and    O
homologous    O
blood    O
serum    O
.    O

Acetylcysteine    B-DerivedFunction106014730
was    O
found    O
to    O
reduce    O
effectiveness    O
of    O
shogaol    O
's    O
apoptotic    O
properties    O
.    O

"N"-Acetylcysteine    B-DerivedFunction106014730
(    O
NAC    O
)    O
is    O
a    O
precursor    O
to    O
glutathione    O
,    O
an    O
antioxidant    O
.    O

Outside    O
North    O
America    O
,    O
mesna    O
is    O
also    O
used    O
as    O
a    O
mucolytic    O
agent    O
,    O
working    O
in    O
the    O
same    O
way    O
as    O
acetylcysteine    B-DerivedFunction106014730
;    O
it    O
is    O
sold    O
for    O
this    O
indication    O
as    O
Mistabron    O
and    O
Mistabronco    O
.    O

As    O
glutathione    O
depletion    O
has    O
been    O
shown    O
to    O
regulate    O
liver    O
toxification    O
,    O
administration    O
of    O
N-acetylcysteine    B-DerivedFunction106014730
in    O
similar    O
doses    O
as    O
given    O
for    O
acetaminophen    O
toxicity    O
have    O
been    O
given    O
to    O
patients    O
.    O

Another    O
class    O
of    O
possible    O
pharmacological    O
treatments    O
are    O
glutamatergic    O
agents    O
such    O
as    O
n-acetyl    B-DerivedFunction106014730
cysteine    I-DerivedFunction106014730
(    O
NAC    O
)    O
.    O

In    O
addition    O
,    O
NAC    O
,    O
or    O
N    O
-    O
acetyl    O
-    O
L    O
-    O
cysteine    O
(    O
acetylcysteine    B-DerivedFunction106014730
)    O
,    O
has    O
been    O
shown    O
to    O
reduce    O
ROS    O
formation    O
associated    O
with    O
the    O
excessive    O
vibrations    O
induced    O
by    O
the    O
noise    O
exposure    O
.    O

Borderline    O
Substances    O
(    O
i.e.    O
Acetylcysteine    B-DerivedFunction106014730
)    O

The    O
Rumack    O
-    O
Matthew    O
nomogram    O
,    O
also    O
known    O
as    O
Rumack    O
-    O
Matthews    O
nomogram    O
or    O
the    O
Acetaminophen    O
nomogram    O
is    O
an    O
acetaminophen    O
toxicity    O
nomogram    O
plotting    O
serum    O
concentration    O
of    O
acetaminophen    O
against    O
the    O
time    O
since    O
ingestion    O
in    O
an    O
attempt    O
to    O
prognosticate    O
possible    O
liver    O
toxicity    O
as    O
well    O
as    O
allowing    O
a    O
clinician    O
to    O
decide    O
whether    O
to    O
proceed    O
with    O
N-Acetylcysteine    B-DerivedFunction106014730
(    O
NAC    O
)    O
treatment    O
or    O
not    O
.    O

Research    O
shows    O
that    O
nitrotyrosine    O
levels    O
can    O
be    O
reduced    O
by    O
N-acetyl    B-DerivedFunction106014730
cysteine    I-DerivedFunction106014730
,    O
which    O
is    O
a    O
precursor    O
to    O
glutathione    O
,    O
one    O
of    O
the    O
body    O
's    O
primary    O
endogenous    O
antioxidants    O
.    O

Furthermore    O
,    O
acetylcysteine    B-DerivedFunction106014730
has    O
been    O
confirmed    O
,    O
in    O
a    O
recent    O
double    O
-    O
blind    O
placebo    O
-    O
controlled    O
trial    O
conducted    O
by    O
the    O
US    O
military    O
,    O
to    O
reduce    O
the    O
effects    O
of    O
blast    O
induced    O
mild    O
traumatic    O
brain    O
and    O
neurological    O
injury    O
in    O
soldiers    O
.    O

Penicillium    O
purpurescens    O
"    O
produces    O
hadacidin    B-DerivedFunction106014730
.    O

Biotin    O
is    O
attached    O
to    O
these    O
carboxylase    O
enzymes    O
through    O
an    O
amino    O
acid    O
(    O
the    O
building    O
material    O
of    O
proteins    O
)    O
called    O
lysine    O
,    O
forming    O
a    O
complex    O
called    O
biocytin    B-DerivedFunction106014730
.    O

The    O
tryptophan    B-DerivedFunction106014730
tryptophylquinone    I-DerivedFunction106014730
(    O
TTQ    O
)    O
group    O
of    O
MADH    O
then    O
donates    O
electrons    O
to    O
the    O
copper    O
center    O
of    O
amicyanin    O
,    O
which    O
in    O
turn    O
gives    O
the    O
electrons    O
to    O
the    O
heme    O
of    O
the    O
cytochrome    O
c.    O
In    O
"    O
P.    O
denitrificans    O
"    O
,    O
amicyanin    O
is    O
absolutely    O
required    O
for    O
electron    O
transfer    O
from    O
MADH    O
to    O
c    O
-    O
type    O
cytochromes    O
.    O

:    O
N07CA04    O
Acetylleucine    B-DerivedFunction106014730

Lymecycline    B-DerivedFunction106014730
is    O
a    O
tetracycline    O
broad    O
-    O
spectrum    O
antibiotic    O
marketed    O
by    O
the    O
pharmaceutical    O
company    O
Galderma    O
.    O

CPHPC    B-DerivedFunction106014730
(    O
R-1-[6-[R-2-carboxy    O
-    O
pyrrolidin-1-yl]-6-oxo    O
-    O
hexanoyl    O
]    O
pyrrolidine-2-carboxylic    O
acid    O
)    O
is    O
a    O
proline    O
-    O
derived    O
small    O
molecule    O
able    O
to    O
strip    O
amyloid    O
P    O
(    O
AP    O
)    O
from    O
deposits    O
by    O
reducing    O
levels    O
of    O
circulating    O
serum    O
amyloid    O
P    O
(    O
SAP    O
)    O
.    O

Brivanib    B-DerivedFunction106014730
alaninate    I-DerivedFunction106014730
(    O
BMS-582664    O
)    O
—    O
development    O
terminated    O

These    O
include    O
soy    O
-    O
based    O
formulas    O
,    O
hypoallergenic    O
formulas    O
based    O
on    O
partially    O
or    O
extensively    O
hydrolyzed    O
protein    O
,    O
and    O
free    O
amino    B-DerivedFunction106014730
acid-based    I-DerivedFunction106014730
formula    I-DerivedFunction106014730
such    O
as    O
Neocate    O
,    O
EleCare    O
,    O
and    O
Puramino    O
.    O
'    O

Two    O
units    O
can    O
combine    O
to    O
form    O
3,3'-diiodothyronine    B-DerivedFunction106014730
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
L    O
-    O
threonine    O
and    O
fluoroacetaldehyde    O
,    O
whereas    O
its    O
two    O
products    O
are    O
acetaldehyde    O
and    O
4-fluoro-L-threonine    B-DerivedFunction106014730
.    O

Coffee    B-DerivedFunction106014730
tea    I-DerivedFunction106014730
leaves    I-DerivedFunction106014730

In    O
more    O
recent    O
years    O
,    O
studies    O
have    O
suggested    O
the    O
use    O
of    O
urinary    O
benzylmercapturic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
as    O
the    O
best    O
marker    O
for    O
toluene    O
exposure    O
,    O
because    O
:    O
it    O
is    O
not    O
detected    O
in    O
non    O
-    O
exposed    O
subjects    O
;    O
it    O
is    O
more    O
sensitive    O
than    O
hippuric    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
at    O
low    O
concentrations    O
;    O
it    O
is    O
not    O
affected    O
by    O
eating    O
or    O
drinking    O
;    O
it    O
can    O
detect    O
toluene    O
exposure    O
down    O
to    O
approximately    O
15    O
ppm    O
;    O
and    O
it    O
shows    O
a    O
better    O
quantitative    O
relationship    O
with    O
toluene    O
than    O
hippuric    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
or    O
"    O
o    O
"-    O
cresol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
16-hydroxytabersonine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
16-methoxytabersonine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
5,8,13,13a    O
-    O
tetrahydrocolumbamine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
tetrahydropalmatine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
7-methylxanthine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
3,7-dimethylxanthine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
dimethyl    O
sulfide    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
trimethylsulfonium    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
thiol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
thioether    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
gamma    O
-    O
tocopherol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
alpha    O
-    O
tocopherol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
trans    O
-    O
aconitate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
(    O
E)-3-(methoxycarbonyl)pent-2-enedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
trans    O
-    O
aconitate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
(    O
E)-2-(methoxycarbonylmethyl)butenedioate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
tRNA    O
containing    O
5-methylaminomethyl-2-thiouridylic    O
acid    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
tRNA    O
containing    O
N1-methyladenine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
tRNA    O
containing    O
N6-methyladenine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
tRNA    O
containing    O
5-methylcytosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
tRNA    O
containing    O
N1-methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
tRNA    O
containing    O
N2-Methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
tRNA    O
containing    O
N7-methylguanine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
tRNA    O
containing    O
2'-O    O
-    O
methylguanosine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
containing    O
uridine    O
at    O
position    O
54    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
tRNA    O
containing    O
ribothymidine    O
at    O
position    O
54    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
L    O
-    O
tryptophan    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
L-2-methyltryptophan    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tyramine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
N    O
-    O
methyltyramine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
vitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
7-O    O
-    O
methylvitexin    O
2"-O    O
-    O
beta    O
-    O
L    O
-    O
rhamnoside    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
xanthotoxol    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S-adenosylhomocysteine    B-DerivedFunction106014730
and    O
O    O
-    O
methylxanthotoxol    O
.    O

DPD    O
is    O
produced    O
by    O
degradation    O
of    O
"S"-adenosylhomocysteine    B-DerivedFunction106014730
by    O
the    O
action    O
of    O
the    O
enzyme    O
"    O
S    O
"-    O
ribosylhomocysteinase    O
.    O

The    O
pathway    O
for    O
the    O
synthesis    O
of    O
creatineArg    O
-    O
Arginine    O
;    O
GATM    O
-    O
Glycine    O
amidinotransferase    O
;    O
GAMT    O
-    O
Guanidinoacetate    O
N    O
-    O
methyltransferase    O
;    O
Gly    O
-    O
Glycine    O
;    O
Met    O
-    O
Methionine    O
;    O
SAH    O
-    O
S-adenosyl    B-DerivedFunction106014730
homocysteine    I-DerivedFunction106014730
;    O
SAM    O
-    O
S    O
-    O
adenosyl    O
methionine    O
.    O

According    O
to    O
the    O
official    O
blog    O
of    O
Autism    O
Speaks    O
,    O
James    O
found    O
that    O
autistic    O
children    O
exhibit    O
abnormal    O
folate    O
metabolism    O
that    O
is    O
detectable    O
by    O
higher    O
levels    O
of    O
plasma    O
homocysteine    O
,    O
adenosine    O
,    O
and    O
S-adenosyl-L-homocysteine    B-DerivedFunction106014730
in    O
the    O
mothers    O
of    O
these    O
children    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S-adenosyl-L-homocysteine    B-DerivedFunction106014730
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
inosyl    O
-    O
L    O
-    O
homocysteine    O
and    O
NH3    O
.    O

The    O
5    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
,    O
malonyl    O
-    O
CoA    O
,    O
NADPH    O
,    O
H+    O
,    O
and    O
S    O
-    O
adenosyl    O
-    O
L    O
-    O
methionine    O
,    O
whereas    O
its    O
6    O
products    O
are    O
dihydromonacolin    O
L    O
,    O
CoA    O
,    O
CO2    O
,    O
NADP+    O
,    O
S-adenosyl-L-homocysteine    B-DerivedFunction106014730
,    O
and    O
H2O.    O

Abbreviations    O
:    O
S-Adenosyl-L-homocysteine    B-DerivedFunction106014730
(    O
SAH    O
)    O
,    O
S    O
-    O
adenosyl    O
-    O
L    O
-    O
methionine    O
(    O
SAM    O
)    O
,    O
DNA    O
methyltransferase    O
(    O
DNA    O
MTase    O
)    O
,    O
Uracil    O
-    O
DNA    O
glycosylase    O
(    O
UNG    O
)    O
.    O

It    O
was    O
prepared    O
with    O
coffee    B-DerivedFunction106014730
syrup    I-DerivedFunction106014730
and    O
cold    O
water    O
.    O

The    O
Opera    O
is    O
a    O
rectangular    O
cake    O
composed    O
of    O
three    O
thin    O
layers    O
of    O
almond    O
sponge    O
cake    O
soaked    O
in    O
coffee    B-DerivedFunction106014730
syrup    I-DerivedFunction106014730
alternating    O
between    O
layers    O
of    O
coffee    O
butter    O
cream    O
and    O
chocolate    O
glaze    O
topped    O
with    O
ganache    O
.    O

He    O
was    O
addicted    O
to    O
coffee    B-DerivedFunction106014730
milk    I-DerivedFunction106014730
,    O
which    O
was    O
the    O
reason    O
why    O
he    O
was    O
n't    O
in    O
hibernation    O
himself    O
.    O

4-(γ-Glutamylamino)butanoic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
is    O
molecule    O
that    O
consists    O
of    O
L    O
-    O
glutamate    O
conjugated    O
to    O
γ-aminobutyric    O
acid    O
(    O
GABA    O
)    O
.    O

"para"-Chlorophenylalanine    B-DerivedFunction106014730
(    O
PCPA    O
)    O

"para"-Chlorophenylalanine    B-DerivedFunction106014730
(    O
PCPA    O
)    O

The    O
bifunctional    O
6-phosphofructo-2-kinase    O
/    O
fructose-2,6-bisphosphatase    O
(    O
PFKFB    O
)    O
regulates    O
the    O
steady    O
-    O
state    O
concentration    O
of    O
fructose    B-DerivedFunction106014730
2,6-bisphosphate    I-DerivedFunction106014730
,    O
an    O
activator    O
of    O
a    O
key    O
regulatory    O
enzyme    O
of    O
glycolysis    O
,    O
phosphofructokinase    O
.    O

Phosphofructokinase    O
is    O
an    O
important    O
control    O
point    O
in    O
the    O
glycolytic    O
pathway    O
,    O
since    O
it    O
is    O
one    O
of    O
the    O
irreversible    O
steps    O
and    O
has    O
key    O
allosteric    O
effectors    O
,    O
AMP    O
and    O
fructose    B-DerivedFunction106014730
2,6-bisphosphate    I-DerivedFunction106014730
(    O
F2,6BP    O
)    O
.    O

Fructose    B-DerivedFunction106014730
2,6-bisphosphate    I-DerivedFunction106014730
(    O
F2,6BP    O
)    O
is    O
a    O
very    O
potent    O
activator    O
of    O
phosphofructokinase    O
(    O
PFK-1    O
)    O
that    O
is    O
synthesized    O
when    O
F6P    O
is    O
phosphorylated    O
by    O
a    O
second    O
phosphofructokinase    O
(    O
PFK2    O
)    O
.    O

Opines    B-DerivedFunction106014730

A    O
naturally    O
occurring    O
soil    O
bacterium    O
"    O
Agrobacterium    O
rhizogenes    O
"    O
that    O
contains    O
root    O
-    O
inducing    O
plasmids    O
(    O
also    O
called    O
Ri    O
plasmids    O
)    O
can    O
infect    O
plant    O
roots    O
and    O
cause    O
them    O
to    O
produce    O
a    O
food    O
source    O
for    O
the    O
bacterium    O
,    O
opines    B-DerivedFunction106014730
,    O
and    O
to    O
grow    O
abnormally    O
.    O

Carbocisteine    B-DerivedFunction106014730
(    O
INN    O
)    O
,    O
also    O
called    O
carbocysteine    B-DerivedFunction106014730
(    O
USAN    O
)    O
,    O
is    O
a    O
mucolytic    O
that    O
reduces    O
the    O
viscosity    O
of    O
sputum    O
and    O
so    O
can    O
be    O
used    O
to    O
help    O
relieve    O
the    O
symptoms    O
of    O
chronic    O
obstructive    O
pulmonary    O
disorder    O
(    O
COPD    O
)    O
and    O
bronchiectasis    O
by    O
allowing    O
the    O
sufferer    O
to    O
bring    O
up    O
sputum    O
more    O
easily    O
.    O

After    O
ingestion    O
,    O
fructose    O
is    O
converted    O
to    O
fructose-1-phosphate    B-DerivedFunction106014730
in    O
the    O
liver    O
by    O
fructokinase    O
.    O
Deficiencies    O
of    O
fructokinase    O
cause    O
essential    O
fructosuria    O
,    O
a    O
clinically    O
benign    O
condition    O
characterized    O
by    O
the    O
excretion    O
of    O
unmetabolized    O
fructose    O
in    O
the    O
urine    O
.    O

Aldolase    O
can    O
also    O
produce    O
DHAP    O
from    O
other    O
(    O
3S,4R)-ketose    O
1-phosphates    O
such    O
as    O
fructose    B-DerivedFunction106014730
1-phosphate    I-DerivedFunction106014730
and    O
sedoheptulose    O
1,7-bisphosphate    O
.    O

Dextrothyroxine    B-DerivedFunction106014730
(    O
trade    O
name    O
Choloxin    B-DerivedFunction106014730
)    O
saw    O
research    O
as    O
a    O
cholesterol    O
-    O
lowering    O
drug    O
but    O
was    O
pulled    O
due    O
to    O
cardiac    O
side    O
-    O
effects    O
.    O

Acetylmuramic    O
acid    O
,    B-DerivedFunction106014730
or    I-DerivedFunction106014730
"'MurNAc    I-DerivedFunction106014730
,    O
is    O
the    O
ether    O
of    O
lactic    O
acid    O
and    O
"    O
N    O
"-    O
acetylglucosamine    O
with    O
a    O
chemical    O
formula    O
of    O
C11H19NO8    O
.    O

(    O
1    O
)    O
formation    O
of    O
UDP    O
-    O
N-acetylmuramic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
(    O
UDPMurNAc    O
)    O
from    O
N    O
-    O
acetylglucosamine    O
(    O
GlcNAc    O
)    O
.    O

These    O
four    O
Mur    O
ligases    O
are    O
responsible    O
for    O
the    O
successive    O
additions    O
of    O
L    O
-    O
alanine    O
,    O
D    O
-    O
glutamate    O
,    O
meso    O
-    O
diaminopimelate    O
or    O
L    O
-    O
lysine    O
,    O
and    O
D    O
-    O
alanyl    O
-    O
D    O
-    O
alanine    O
to    O
UDP    O
-    O
N-acetylmuramic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
.    O

Hence    O
,    O
this    O
enzyme    O
has    O
one    O
substrate    O
,    O
alpha-D-mannose    B-DerivedFunction106014730
1-phosphate    I-DerivedFunction106014730
,    O
and    O
one    O
product    O
,    O
D-mannose    B-DerivedFunction106014730
6-phosphate    I-DerivedFunction106014730
.    O

GlcNAc-1-phosphotransferase    O
catalyzes    O
the    O
N    O
-    O
linked    O
glycosylation    O
of    O
asparagine    O
residues    O
with    O
a    O
molecule    O
called    O
mannose-6-phosphate    B-DerivedFunction106014730
(    O
M6P    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
D    O
-    O
mannose    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
D-mannose    B-DerivedFunction106014730
6-phosphate    I-DerivedFunction106014730
.    O

The    O
precursor    O
to    O
the    O
lachrymatory    O
compound    O
,    O
(    O
RS    O
,    O
RC)-("E")-"S"-(1-butenyl    O
)    O
cysteine    O
"    O
S    O
"-    O
oxide    O
(    O
alliin    B-DerivedFunction106014730
)    O
,    O
was    O
isolated    O
from    O
homogenates    O
of    O
"    O
A.    O
siculum    O
"    O
,    O
and    O
a    O
closely    O
related    O
species    O
,    O
"    O
Allium    O
tripedale    O
"    O
,    O
and    O
fully    O
characterized    O
.    O

Cysteine    O
sulphoxides    O
are    O
also    O
largely    O
responsible    O
for    O
the    O
flavour    O
and    O
spicy    O
taste    O
of    O
these    O
species    O
,    O
predominantly    O
the    O
isomeric    O
cysteine    O
derivatives    O
alliin    B-DerivedFunction106014730
and    O
isoalliin    O
.    O

A    O
drink    O
made    O
from    O
coffee    O
husks    O
called    O
qishr    B-DerivedFunction106014730
is    O
also    O
enjoyed    O
.    O

Popular    O
counterions    O
are    O
glycine    O
and    O
tricine    B-DerivedFunction106014730
.    O

There    O
are    O
many    O
Linux    O
distributions    O
created    O
with    O
privacy    O
,    O
secrecy    O
,    O
network    O
anonymity    O
and    O
information    O
security    O
in    O
mind    O
,    O
including    O
Tails    O
,    O
Tin    B-DerivedFunction106014730
Hat    I-DerivedFunction106014730
Linux    I-DerivedFunction106014730
and    O
Tinfoil    O
Hat    O
Linux    O
.    O

Orthanilic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730

Thermolysin    O
complexed    O
with    O
the    O
inhibitor    O
(    O
"    O
thiorphan    B-DerivedFunction106014730
are    O
isomeric    O
thiol    O
-    O
containing    O
inhibitors    O
of    O
endopeptidase    O
EC    O
24    O
-    O
11    O
(    O
also    O
called    O
"    O
enkephalinase    O
"    O
)    O
.    O

carglumic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
(    O
USAN    O
)    O

Conjugation    O
with    O
glycine    O
forms    O
salicyluric    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
,    O
and    O
with    O
glucuronic    O
acid    O
to    O
form    O
two    O
different    O
glucuronide    O
esters    O
.    O

Acivicin    B-DerivedFunction106014730
is    O
an    O
analog    O
of    O
glutamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
agaritine    B-DerivedFunction106014730
and    O
acceptor    O
,    O
whereas    O
its    O
two    O
products    O
are    O
4-hydroxymethylphenylhydrazine    O
and    O
gamma    O
-    O
L    O
-    O
glutamyl    O
-    O
acceptor    O
.    O

Streptomyces    O
alanosinicus    O
"    O
produces    O
the    O
antibiotics    O
alanosine    B-DerivedFunction106014730
and    O
spicamycin    O
.    O

OCD    O
has    O
been    O
associated    O
with    O
reduced    O
N-Acetylaspartic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
in    O
the    O
mPFC    O
,    O
which    O
is    O
thought    O
to    O
reflect    O
neuron    O
density    O
or    O
functionality    O
,    O
although    O
the    O
exact    O
interpretation    O
has    O
not    O
been    O
established    O
.    O

Moreover    O
,    O
evidence    O
suggests    O
that    O
adverse    O
changes    O
in    O
the    O
level    O
of    O
biomarkers    O
of    O
metabolic    O
integrity    O
and    O
synthesis    O
occur    O
in    O
recreational    O
users    O
,    O
such    O
as    O
a    O
reduction    O
in    O
"N"-acetylaspartate    B-DerivedFunction106014730
and    O
creatine    O
levels    O
and    O
elevated    O
levels    O
of    O
choline    O
and    O
myoinositol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
acetyl    O
-    O
CoA    O
and    O
L    O
-    O
aspartate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CoA    O
and    O
N-acetyl-L-aspartate    B-DerivedFunction106014730
.    O

Thymectacin    B-DerivedFunction106014730
(    O
NB-1011    O
,    O
NB-101    O
,    O
N-[[5-[(E)-2-Bromovinyl]-2'-deoxyuridin-5'-O    O
-    O
yl]](phenoxy)phosphoryl]-L    O
-    O
alanine    O
methyl    O
ester    O
)    O
is    O
an    O
anticancer    O
prodrug    O
of    O
brivudine    O
monophosphate    O
.    O

Tetrazolylglycine    B-DerivedFunction106014730
(    O
Tet-Gly    B-DerivedFunction106014730
,    O
LY-285,265    B-DerivedFunction106014730
)    O
is    O
a    O
potent    O
and    O
selective    O
NMDA    O
receptor    O
agonist    O
,    O
stimulating    O
the    O
NMDA    O
receptor    O
with    O
higher    O
potency    O
than    O
either    O
glutamate    O
or    O
NMDA    B-DerivedFunction106014730
.    O

m    O
-    O
Hydroxyphenylglycine    O
and    O
3,5-dihydroxyphenylglycine    B-DerivedFunction106014730
are    O
two    O
amino    O
acids    O
that    O
can    O
be    O
isolated    O
from    O
the    O
latex    O
of    O
"    O
E.    O
helioscopia    O
"    O
.    O

N    O
-    O
acetylglutamate    O
synthase    O
(    O
NAGS    O
)    O
is    O
an    O
enzyme    O
that    O
catalyses    O
the    O
production    O
of    O
"N"-Acetylglutamate    B-DerivedFunction106014730
(    O
NAG    O
)    O
from    O
glutamate    O
and    O
acetyl    O
-    O
CoA.    O

Nova    B-DerivedFunction106014730
Linux    I-DerivedFunction106014730

Nova    B-DerivedFunction106014730
(operating    I-DerivedFunction106014730
system)    I-DerivedFunction106014730

glutaurine    B-DerivedFunction106014730
(    O
INN    O
)    O

Ombrabulin    B-DerivedFunction106014730
was    O
an    O
experimental    O
drug    O
candidate    O
discovered    O
by    O
Ajinomoto    O
and    O
further    O
developed    O
by    O
Sanofi    O
-    O
Aventis    O
.    O

Portage    O
is    O
a    O
package    O
management    O
system    O
originally    O
created    O
for    O
and    O
used    O
by    O
Gentoo    O
Linux    O
and    O
also    O
by    O
Chrome    O
OS    O
,    O
Sabayon    B-DerivedFunction106014730
,    O
and    O
Funtoo    O
Linux    O
among    O
others    O
.    O

SabayonLinux    B-DerivedFunction106014730

Sabayon    B-DerivedFunction106014730
Linux    I-DerivedFunction106014730

At    O
this    O
stage    O
,    O
phosphoenolpyruvate    O
and    O
erythrose-4-phosphate    O
react    O
to    O
form    O
3-deoxy-D-arabinoheptulosonate-7-phosphate    B-DerivedFunction106014730
(    O
DAHP    O
)    O
,    O
in    O
a    O
reaction    O
catalyzed    O
by    O
the    O
enzyme    O
DAHP    O
synthase    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
GDP    O
and    O
alpha-D-mannose    B-DerivedFunction106014730
1-phosphate    I-DerivedFunction106014730
,    O
whereas    O
its    O
two    O
products    O
are    O
phosphate    O
and    O
GDP    O
-    O
mannose    O
.    O

It    O
is    O
made    O
from    O
a    O
combination    O
of    O
imipenem    O
and    O
cilastatin    B-DerivedFunction106014730
.    O

It    O
is    O
a    O
broad    O
-    O
spectrum    O
beta    O
-    O
lactam    O
containing    O
equal    O
quantities    O
of    O
imipenem    O
and    O
cilastatin    B-DerivedFunction106014730
.    O

Diiodotyrosine    B-DerivedFunction106014730
(    O
DIT    O
)    O
is    O
a    O
precursor    O
in    O
the    O
production    O
of    O
thyroid    O
hormone    O
,    O
and    O
results    O
from    O
iodization    O
of    O
monoiodotyrosine    B-DerivedFunction106014730
at    O
the    O
other    O
meta-    O
position    O
on    O
the    O
phenol    O
ring    O
.    O

One    O
unit    O
can    O
combine    O
with    O
diiodotyrosine    B-DerivedFunction106014730
to    O
form    O
triiodothyronine    O
,    O
as    O
occurs    O
in    O
the    O
colloid    O
of    O
the    O
thyroid    O
follicle    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
1-deoxy-D-xylulose    B-DerivedFunction106014730
5-phosphate    I-DerivedFunction106014730
and    O
3-amino-2-oxopropyl    O
phosphate    O
,    O
whereas    O
its    O
3    O
products    O
are    O
pyridoxine    O
5'-phosphate    O
,    O
phosphate    O
,    O
and    O
H2O.    O

:    O
H03BX02    O
Dibromotyrosine    B-DerivedFunction106014730

FireballISO    B-DerivedFunction106014730
–    O
VMware    O
virtual    O
machine    O
that    O
generates    O
a    O
customized    O
security    O
-    O
hardened    O
IPv4    O
and    O
IPv6    O
firewall    O
live    O
CD    O
.    O

Nitrosoproline    B-DerivedFunction106014730
is    O
a    O
nitroso    O
derivative    O
of    O
the    O
amino    O
acid    O
proline    O
.    O

Tetrazolylglycine    B-DerivedFunction106014730
(    O
Tet-Gly    B-DerivedFunction106014730
,    O
LY-285,265    B-DerivedFunction106014730
)    O
is    O
a    O
potent    O
and    O
selective    O
NMDA    O
receptor    O
agonist    O
,    O
stimulating    O
the    O
NMDA    O
receptor    O
with    O
higher    O
potency    O
than    O
either    O
glutamate    O
or    O
NMDA    B-DerivedFunction106014730
.    O

Memantine    O
is    O
a    O
NMDA    B-DerivedFunction106014730
receptor    O
antagonist    O
and    O
is    O
used    O
to    O
treat    O
patients    O
with    O
moderate    O
to    O
severe    O
Alzheimer    O
's    O
disease    O
,    O
but    O
is    O
also    O
used    O
as    O
a    O
neuroenhancement    O
drug    O
.    O

Several    O
adverse    O
biological    O
events    O
contribute    O
to    O
this    O
secondary    O
deterioration    O
,    O
including    O
:    O
release    O
of    O
excitatory    O
amino    O
acids    O
which    O
activate    O
N-methyl-D-aspartate    B-DerivedFunction106014730
(    O
NMDA    O
)    O
and    O
amino-3-hydroxy-5-methyl-4-isoxazolepropionate    O
(    O
AMPA    O
)    O
receptors    O
on    O
neurons    O
(    O
30,37    O
)    O
and    O
oligodendroglial    O
precursors    O
,    O
accumulation    O
of    O
excitatory    O
neurotransmitters    O
,    O
generation    O
of    O
reactive    O
oxygen    O
radicals    O
,    O
intracellular    O
calcium    O
accumulation    O
and    O
mitochondrial    O
dysfunction    O
.    O

In    O
dendritic    O
spines    O
,    O
SK    O
channels    O
are    O
directly    O
coupled    O
to    O
NMDA    B-DerivedFunction106014730
receptors    O
.    O

LTP    O
is    O
dependent    O
on    O
the    O
activity    O
of    O
NMDA    O
receptors    O
in    O
the    O
brain    O
and    O
it    O
has    O
been    O
shown    O
that    O
NMDA    B-DerivedFunction106014730
activity    O
influences    O
acetylation    O
.    O

Tolerance    O
results    O
in    O
a    O
desensitization    O
of    O
GABA    O
receptors    O
and    O
an    O
increased    O
sensitization    O
of    O
the    O
excitatory    O
neurotransmitter    O
system    O
,    O
glutamate    O
such    O
as    O
NMDA    B-DerivedFunction106014730
glutamate    O
receptors    O
.    O

Homocysteic    O
acid    O
is    O
a    O
sulfur    O
-    O
containing    O
glutamic    O
acid    O
analog    O
and    O
a    O
potent    O
NMDA    B-DerivedFunction106014730
receptor    O
agonist    O
.    O

Toxicity    O
may    O
also    O
result    O
from    O
the    O
pharmacological    O
properties    O
of    O
the    O
drug    O
;    O
excess    O
NMDA    B-DerivedFunction106014730
antagonism    O
can    O
completely    O
block    O
calcium    O
influx    O
into    O
neurons    O
and    O
provoke    O
cell    O
death    O
through    O
apoptosis    O
,    O
although    O
this    O
is    O
more    O
likely    O
to    O
be    O
a    O
long    O
-    O
term    O
result    O
of    O
chronic    O
solvent    O
abuse    O
than    O
a    O
consequence    O
of    O
short    O
-    O
term    O
use    O
.    O

During    O
postdoctoral    O
studies    O
at    O
the    O
Australian    O
National    O
University    O
with    O
David    O
Curtis    O
,    O
he    O
helped    O
establish    O
the    O
role    O
of    O
glutamate    O
as    O
a    O
central    O
neurotransmitter    O
and    O
characterised    O
its    O
actions    O
between    O
AMPA    O
,    O
N-Methyl-D-aspartic    B-DerivedFunction106014730
acid    I-DerivedFunction106014730
(NMDA)    I-DerivedFunction106014730
and    O
kainate    O
receptor    O
subtypes    O
.    O

Excitotoxins    O
like    O
NMDA    B-DerivedFunction106014730
and    O
kainic    O
acid    O
which    O
bind    O
to    O
these    O
receptors    O
,    O
as    O
well    O
as    O
pathologically    O
high    O
levels    O
of    O
glutamate    O
,    O
can    O
cause    O
excitotoxicity    O
by    O
allowing    O
high    O
levels    O
of    O
calcium    O
ions    O
(    O
Ca2    O
+    O
)    O
to    O
enter    O
the    O
cell    O
.    O

Following    O
research    O
,    O
excitotoxicity    O
appears    O
to    O
be    O
the    O
likely    O
mode    O
of    O
action    O
for    O
BMAA    O
which    O
acts    O
as    O
a    O
glutamate    O
agonist    O
,    O
activating    O
AMPA    O
and    O
NMDA    B-DerivedFunction106014730
receptors    O
and    O
causing    O
damage    O
to    O
cells    O
even    O
at    O
relatively    O
low    O
concentrations    O
of    O
10    O
μM.    O
The    O
subsequent    O
uncontrolled    O
influx    O
of    O
Ca2    O
+    O
then    O
leads    O
to    O
the    O
pathophysiology    O
described    O
above    O
.    O

Propiram    O
exhibits    O
weak    O
opioid    O
antagonist    O
activity    O
on    O
the    O
mu    O
receptor    O
—    O
quite    O
a    O
bit    O
weaker    O
than    O
its    O
agonist    O
effects    O
—    O
and    O
the    O
effect    O
on    O
kappa    O
and    O
delta    O
opioid    O
,    O
sigma    O
receptors    O
,    O
or    O
the    O
NMDA    B-DerivedFunction106014730
system    O
are    O
not    O
well    O
understood    O
.    O

Dextromethorphan    O
has    O
been    O
noted    O
to    O
slow    O
the    O
development    O
of    O
tolerance    O
to    O
opioids    O
and    O
exert    O
additional    O
analgesia    O
by    O
acting    O
upon    O
the    O
NMDA    B-DerivedFunction106014730
receptors    O
;    O
some    O
analgesics    O
such    O
as    O
methadone    O
and    O
ketobemidone    O
and    O
perhaps    O
piritramide    O
have    O
intrinsic    O
NMDA    O
action    O
.    O

blocking    O
N    O
-    O
methyl    O
-    O
D    O
-    O
aspartate    O
(    O
NMDA    B-DerivedFunction106014730
)    O
glutamate    O
receptors    O
,    O
an    O
excitatory    O
neurotransmitter    O
of    O
the    O
central    O
nervous    O
system    O
.    O

This    O
is    O
important    O
for    O
the    O
study    O
of    O
the    O
TAAR1    O
receptor    O
,    O
as    O
while    O
numerous    O
other    O
compounds    O
are    O
known    O
which    O
act    O
as    O
TAAR1    O
agonists    O
,    O
such    O
as    O
methamphetamine    O
,    O
MDMA    O
and    O
3-iodothyronamine    B-DerivedFunction106014730
,    O
all    O
previously    O
known    O
TAAR1    O
agonists    O
are    O
either    O
weak    O
and    O
rapidly    O
metabolized    O
(    O
endogenous    O
ligands    O
)    O
,    O
or    O
have    O
strong    O
pharmacological    O
activity    O
at    O
other    O
targets    O
(    O
amphetamines    O
,    O
thyronamines    O
)    O
,    O
making    O
it    O
very    O
difficult    O
to    O
assess    O
which    O
effects    O
are    O
due    O
to    O
TAAR1    O
activation    O
.    O

3-Iodothyronamine    B-DerivedFunction106014730

3-Iodotyrosine    B-DerivedFunction106014730
•    O

:    O
C10AD03    O
Nicofuranose    B-DerivedFunction106014730

Citiolone    B-DerivedFunction106014730
is    O
a    O
drug    O
used    O
in    O
liver    O
therapy    O
.    O

Reverse    B-DerivedFunction106014730
T3    I-DerivedFunction106014730
levels    O
are    O
generally    O
increased    O
signifying    O
inhibition    O
of    O
normal    O
type    O
1    O
deiodinase    O
or    O
reduced    O
clearance    O
of    O
reverse    O
T3    O
.    O

"    O
Inactivation    O
"    O
of    O
thyroid    O
hormones    O
occurs    O
by    O
removal    O
of    O
an    O
iodine    O
atom    O
on    O
the    O
inner    O
ring    O
,    O
which    O
converts    O
thyroxine    O
to    O
the    O
inactive    O
reverse    B-DerivedFunction106014730
triiodothyronine    I-DerivedFunction106014730
(    O
rT3    O
)    O
,    O
or    O
which    O
converts    O
the    O
active    O
triiodothyronine    O
to    O
diiodothyronine    O
(    O
T2    O
)    O
.    O

Hepapressin    B-DerivedFunction106014730
is    O
an    O
amino    O
acid    O
complex    O
prepared    O
from    O
Argentinian    O
bovine    O
liver    O
.    O

Procyanidin    O
B2    O
has    O
been    O
shown    O
to    O
inhibit    O
the    O
formation    O
of    O
the    O
advanced    O
glycation    O
end    O
-    O
products    O
pentosidine    O
,    O
carboxymethyllysine    B-DerivedFunction106014730
(    O
CML    O
)    O
,    O
and    O
methylglyoxal    O
(    O
MGO    O
)    O
.    O

In    O
the    O
first    O
step    O
of    O
the    O
biosynthesis    O
these    O
two    O
amino    O
acids    O
are    O
combined    O
by    O
the    O
enzyme    O
arginine    O
:    O
glycine    O
amidinotransferase    O
(    O
AGAT    O
,    O
EC:2.1.4.1    O
)    O
to    O
form    O
guanidinoacetate    B-DerivedFunction106014730
,    O
which    O
is    O
then    O
methylated    O
by    O
guanidinoacetate    O
N    O
-    O
methyltransferase    O
(    O
GAMT    O
,    O
EC:2.1.1.2    O
)    O
,    O
using    O
S    O
-    O
adenosyl    O
methionine    O
as    O
the    O
methyl    O
donor    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
guanidinoacetate    B-DerivedFunction106014730
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
phosphoguanidinoacetate    O
.    O

3,5,3'-Triiodothyronamine    B-DerivedFunction106014730
(    O
T3AM    O
)    O

L-Arginine    B-DerivedFunction106014730
ethyl    I-DerivedFunction106014730
ester    I-DerivedFunction106014730


